Skip to content

EBITDA at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$134M+483%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-$5.69M+78.0%
Johnson & Johnson logo
Johnson & JohnsonJNJ
Glaukos logo
GlaukosGKOS
AbbVie logo
AbbVieABBV
Schering-Plough logo
Schering-PloughSGP

Other financials

Income statement

See full
Revenue$19.7M+12.5%
Gross profit$17.0M+12.5%
Operating income-$12.4M+10.4%
Net income-$13.0M+8.3%
EPS (diluted)-$0.24+14.3%

Balance sheet

See full
Cash & equivalents$85.0M-21.9%
Total debt$40.9M+1.1%
Total equity$53.9M-30.6%
Total assets$109.7M-15.4%

Cash flow

See full
Operating cash flow-$7.0M+39.4%
CapEx$60.0K
Free cash flow-$7.1M+38.9%

Valuation

See full
Market cap$294.9M+35.0%
Enterprise value$250.83M+59.0%
P/S3.7×+0.8×

Profitability

See full
Gross margin86.2%+0.5pp
Operating margin-44.8%-10.2pp
Net margin-46.8%-9.6pp
FCF margin-31.9%+0.2pp

Returns & leverage

See full
Return on equity-56.6%+4.3pp
Debt / equity0.8×+0.2×
Current ratio5.9×-4.6×

Where this comes from

Calculated from Sight Sciences, Inc.’s reported figures.

$12.4Mebit+
$103.0KDepreciation Depletion & Amortization
=-$12.31M

The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sight Sciences, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sight Sciences, Inc.'s EBITDA?
Sight Sciences, Inc. (SGHT) reported EBITDA of -$12.31M in Q1 2026.
How has Sight Sciences, Inc.'s EBITDA changed year-over-year?
Sight Sciences, Inc.'s EBITDA increased by 10.2% year-over-year, from -$13.71M to -$12.31M.
What is the long-term trend for Sight Sciences, Inc.'s EBITDA?
Over 4 years (2021 to 2025), Sight Sciences, Inc.'s EBITDA has grown at a -7.8% compound annual growth rate (CAGR), from -$50.77M to -$36.61M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.